POWERFUL:Zero pain, sustained1,3
Pain freedom at 2 hours (co-primary endpoint) was demonstrated in 21% (UBRELVY® 50 mg) vs 13% (placebo).1,3 Sustained pain freedom from 2 to 24 hours (secondary endpoint) was achieved in 14% (UBRELVY 50 mg) vs 8% (placebo)1,3,4
RAPID:Quick pain relief1
Pain relief at 2 hours was demonstrated in 62% (UBRELVY 50 mg) vs 49% (placebo) when taken immediately or within 4 hours of onset1,3,5
PRE-HEADACHE:Clinical evidence3
Absence of headache pain of moderate to severe intensity within 24 hours after dosing in the pre-headache phase (primary endpoint)3
INDICATION
UBRELVY® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

Get patients started
Once you've decided to prescribe UBRELVY, enable access for your patients with our U-CONCIERGE program and learn how eligible patients may pay as little as $0—all pills, all fills.†
Help enable access
16-count pack is available for your UBRELVY patients
Migraine attacks can be unpredictable.6 Prepare your patients with a 16-count package of UBRELVY 100 mg tablets.
View dosingMany patients experience
pre-headache symptoms7
See the results of administering UBRELVY during the pre-headache phase of a migraine attack.
Explore pre-headache data*In clinical studies, patients took UBRELVY within 4 hours of a migraine attack.5
†Patient out-of-pocket costs may vary. Terms and Conditions apply. This offer is only valid for commercially insured patients. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs.